Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer

Su Y.¹ , Liu Y.¹ , Behrens C.R.¹ , Bidlingmaier S.¹ , Lee N.K.¹ , Liu B.^{1, 3} , Aggarwal R.^{3, 2} , Sherbenou D.W.² , Shuman M.A.^{2, 6} , Small E.J.^{3, 2, 6} , Hann B.C.³ , Simko J.P.^{3, 5} , Premasekharan G.^{3, 6} , Paris P.L.^{3, 6} , Burlingame A.L. ⁴ , Seo Y.⁷

JCI Insight

17

Английский

Опубликовано

10.1172/jci.insight.121497

3

2018

• ¹ Department of Anesthesia
• ² Helen Diller Family Comprehensive Cancer Center
• ³ Department of Medicine
• ⁴ Department of Urology
• ⁵ Department of Pathology
• ⁶ Department of Pharmaceutical Chemistry
• ⁷ Department of Radiology and Biomedical Imaging|UCSF

07.11.2019

07.11.2019

https://repository.rudn.ru/ru/records/article/record/51264/